Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Clinical Diabetology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2022

open access

Vol 7, No 4 (2018)
Research paper
Submitted: 2018-06-04
Accepted: 2018-07-22
Published online: 2018-09-11
View PDF Download PDF file
Get Citation

Overexpression of miR-652-5p in new onset type 1 diabetes

Magdalena Zurawek1, Agnieszka Dzikiewicz-Krawczyk1, Katarzyna Izykowska1, Iwona Ziolkowska-Suchanek1, Bogda Skowronska2, Maria Czainska3, Marta Kazimierska1, Marta Podralska1, Piotr Fichna2, Grzegorz Krzysztof Przybylski1, Jerzy Nowak1, Marta Fichna14, Natalia Rozwadowska1
DOI: 10.5603/DK.2018.0019
·
CD 2018;7(4):189-195.
Affiliations
  1. Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland, Strzeszynska 32, 60-479 Poznan, Poland
  2. Department of Paediatric Diabetes and Obesity, Poznan University of Medical Sciences, Poznan, Poland
  3. Family Physician Clinic, Murowana Goslina, Poland
  4. Department of Endocrinology and Metabolism, Poznan University of Medical Sciences, Poznan, Poland

open access

Vol 7, No 4 (2018)
Research papers
Submitted: 2018-06-04
Accepted: 2018-07-22
Published online: 2018-09-11

Abstract

Introduction. MicroRNAs (miRNAs) are small noncoding RNA regulating gene expression at the posttranscriptional level. miRNAs have emerged as an important regulators of central and peripheral immune tolerance, therefore study the RNA molecules in the context of type 1 diabetes (T1D) pathogenesis is an important issue. The aim of this study was to investigate miR-652-5p expression level in the new onset T1D and an impact on ADAR and MARCH5, potential target genes. Material and methods. The miR-652-5p expression was investigated in the peripheral blood mononuclear cell of newly diagnosed T1D pediatric patients (n = 28) and age-matched controls (n = 28) by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). miRNA targets were analyzed by luciferase reporter assays. Results. Expression analysis revealed upregulation of miR-652-5p in T1D group compared to non-diabetic controls (p < 0.05). Luciferase reporter assay did not indicated ADAR and MARCH5 as miR-652-5p targets. Conclusion. Our study revealed miR-652-5p as potential marker of new onset type 1 diabetes.

Abstract

Introduction. MicroRNAs (miRNAs) are small noncoding RNA regulating gene expression at the posttranscriptional level. miRNAs have emerged as an important regulators of central and peripheral immune tolerance, therefore study the RNA molecules in the context of type 1 diabetes (T1D) pathogenesis is an important issue. The aim of this study was to investigate miR-652-5p expression level in the new onset T1D and an impact on ADAR and MARCH5, potential target genes. Material and methods. The miR-652-5p expression was investigated in the peripheral blood mononuclear cell of newly diagnosed T1D pediatric patients (n = 28) and age-matched controls (n = 28) by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). miRNA targets were analyzed by luciferase reporter assays. Results. Expression analysis revealed upregulation of miR-652-5p in T1D group compared to non-diabetic controls (p < 0.05). Luciferase reporter assay did not indicated ADAR and MARCH5 as miR-652-5p targets. Conclusion. Our study revealed miR-652-5p as potential marker of new onset type 1 diabetes.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

T1D; expression; miR-652-5p; ADAR; MARCH5

About this article
Title

Overexpression of miR-652-5p in new onset type 1 diabetes

Journal

Clinical Diabetology

Issue

Vol 7, No 4 (2018)

Article type

Research paper

Pages

189-195

Published online

2018-09-11

Page views

5944

Article views/downloads

733

DOI

10.5603/DK.2018.0019

Bibliographic record

CD 2018;7(4):189-195.

Keywords

T1D
expression
miR-652-5p
ADAR
MARCH5

Authors

Magdalena Zurawek
Agnieszka Dzikiewicz-Krawczyk
Katarzyna Izykowska
Iwona Ziolkowska-Suchanek
Bogda Skowronska
Maria Czainska
Marta Kazimierska
Marta Podralska
Piotr Fichna
Grzegorz Krzysztof Przybylski
Jerzy Nowak
Marta Fichna
Natalia Rozwadowska

References (35)
  1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010; 464(7293): 1293–1300.
    PubMed
  2. Davies JL, Kawaguchi Y, Bennett ST, et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature. 1994; 371(6493): 130–136.
    CrossRefPubMed
  3. Aly TA, Ide A, Jahromi MM, et al. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci U S A. 2006; 103(38): 14074–14079.
    CrossRefPubMed
  4. Ueda H, Howson JMM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003; 423(6939): 506–511.
    CrossRefPubMed
  5. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004; 36(4): 337–338.
    CrossRefPubMed
  6. Smyth DJ, Cooper JD, Bailey R, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet. 2006; 38(6): 617–619.
    CrossRefPubMed
  7. Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet. 2007; 39(9): 1074–1082.
    CrossRefPubMed
  8. Vaarala O, Klemetti P, Juhela S, et al. Effect of coincident enterovirus infection and cows' milk exposure on immunisation to insulin in early infancy. Diabetologia. 2002; 45(4): 531–534.
    CrossRefPubMed
  9. Wasmuth HE, Kolb H. Cow's milk and immune-mediated diabetes. Proc Nutr Soc. 2000; 59(4): 573–579.
    PubMed
  10. Wen Li, Ley RE, Volchkov PYu, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008; 455(7216): 1109–1113.
    CrossRefPubMed
  11. Weintrob N, Sprecher E, Israel S, et al. Type 1 diabetes environmental factors and correspondence analysis of HLA class II genes in the Yemenite Jewish community in Israel. Diabetes Care. 2001; 24(4): 650–653.
    PubMed
  12. Brown CC, Wedderburn LR. Genetics: Mapping autoimmune disease epigenetics: what's on the horizon? Nat Rev Rheumatol. 2015; 11(3): 131–132.
    CrossRefPubMed
  13. Jeffries MA, Sawalha AH. Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve? Expert Rev Clin Immunol. 2015; 11(1): 45–58.
    CrossRefPubMed
  14. Simpson LJ, Ansel KM. MicroRNA regulation of lymphocyte tolerance and autoimmunity. J Clin Invest. 2015; 125(6): 2242–2249.
    CrossRefPubMed
  15. Baumjohann D, Ansel KM. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat Rev Immunol. 2013; 13(9): 666–678.
    CrossRefPubMed
  16. O'Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annu Rev Immunol. 2012; 30: 295–312.
    CrossRefPubMed
  17. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell. 2009; 136(1): 26–36.
    CrossRefPubMed
  18. Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008; 132(5): 875–886.
    CrossRefPubMed
  19. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008; 9(4): 405–414.
    CrossRefPubMed
  20. Li QJ, Chau J, Ebert PJR, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007; 129(1): 147–161.
    CrossRefPubMed
  21. Kang SG, Liu WH, Lu P, et al. MicroRNAs of the miR-17∼92 family are critical regulators of T(FH) differentiation. Nat Immunol. 2013; 14(8): 849–857.
    CrossRefPubMed
  22. Zheng Y, Wang Z, Zhou Z. miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes. Cell Mol Immunol. 2017; 14(6): 488–496.
    CrossRefPubMed
  23. Zurawek M, Dzikiewicz-Krawczyk A, Izykowska K, et al. miR-487a-3p upregulated in type 1 diabetes targets CTLA4 and FOXO3. Diabetes Res Clin Pract. 2018 [Epub ahead of print]; 142: 146–153.
    CrossRefPubMed
  24. Rice GI, Kasher PR, Forte GMA, et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet. 2012; 44(11): 1243–1248.
    CrossRefPubMed
  25. Shao WH, Shu DH, Zhen Y, et al. Prion-like Aggregation of Mitochondrial Antiviral Signaling Protein in Lupus Patients Is Associated With Increased Levels of Type I Interferon. Arthritis Rheumatol. 2016; 68(11): 2697–2707.
    CrossRefPubMed
  26. Fourlanos S, Varney MD, Tait BD, et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care. 2008; 31(8): 1546–1549.
    CrossRefPubMed
  27. Hezova R, Slaby O, Faltejskova P, et al. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol. 2010; 260(2): 70–74.
    CrossRefPubMed
  28. Yang M, Ye L, Wang B, et al. Decreased miR-146 expression in peripheral blood mononuclear cells is correlated with ongoing islet autoimmunity in type 1 diabetes patients 1miR-146. J Diabetes. 2015; 7(2): 158–165.
    CrossRefPubMed
  29. Sebastiani G, Grieco FA, Spagnuolo I, et al. Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab Res Rev. 2011; 27(8): 862–866.
    CrossRefPubMed
  30. Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009; 10(12): 1252–1259.
    CrossRefPubMed
  31. Salas-Pérez F, Codner E, Valencia E, et al. MicroRNAs miR-21a and miR-93 are down regulated in peripheral blood mononuclear cells (PBMCs) from patients with type 1 diabetes. Immunobiology. 2013; 218(5): 733–737.
    CrossRefPubMed
  32. Satake E, Pezzolesi MG, Md Dom ZI, et al. Circulating miRNA Profiles Associated With Hyperglycemia in Patients With Type 1 Diabetes. Diabetes. 2018; 67(5): 1013–1023.
    CrossRefPubMed
  33. Rice GI, Forte GMA, Szynkiewicz M, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013; 12(12): 1159–1169.
    CrossRefPubMed
  34. Crow YJ, Chase DS, Lowenstein Schmidt J, et al. Human Disease Phenotypes Associated With Mutations in TREX1. Journal of Clinical Immunology. 2015; 35(3): 296–312.
    CrossRef
  35. Dominguez-Gutierrez PR, Ceribelli A, Satoh M, et al. Elevated signal transducers and activators of transcription 1 correlates with increased C-C motif chemokine ligand 2 and C-X-C motif chemokine 10 levels in peripheral blood of patients with systemic lupus erythematosus. Arthritis Res Ther. 2014; 16(1): R20.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl